BruceStroberMDPhD

PubMed

• Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.
  Sima, A., Janak, J., Patel, M., Photowala, H., Garg, V., Strober, B., Duffin, K., Lebwohl, M., Bagel, J.> ;The Journal of Dermatological Treatment. 2024 Dec 1
• Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
  Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B Gottlieb, Mark Lebwohl, Joseph F Merola, Bruce Strobe...> ;Journal of the American Academy of Dermatology. 2024 Apr 6
• Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
  Andrew Blauvelt, April Armstrong, Joseph F Merola, Bruce Strober, Dirk de Cuyper, Luke Peterson, Owen Davies, Jeffrey L Stark, Mark Lebwohl> ;Journal of the American Academy of Dermatology. 2024 Mar 4
• Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic a...
  Dennis McGonagle, Arthur Kavanaugh, Iain B McInnes, Lars Erik Kristensen, Joseph F Merola, Bruce Strober, Rebecca Bolce, Jeffrey Lisse, Jennifer Pustizzi, Christophe S...> ;Rheumatology. 2024 Feb 10
• 1 citations
  Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial ...
  Jonathan I Silverberg, Bruce Strober, Brian Feinstein, Jinhua Xu, Emma Guttman-Yassky, Eric L Simpson, Pauline Li, Malinda Longphre, Jing Song, Jiawang Guo, Jang Yun, ...> ;The Journal of Allergy and Clinical Immunology. 2024 Apr 1
• 1 citations
  Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
  Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F Merola, Mark Lebwohl, Akimichi Morita, Jacek C Szepietowski, Jo Lambert, Lauren Hippeli, Elizabeth ...> ;Journal of the American Academy of Dermatology. 2024 Apr 1
• 2 citations
  Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
  Richard B Warren, Lars E French, Andrew Blauvelt, Richard G Langley, Alexander Egeberg, Ulrich Mrowietz, Hamish J A Hunter, Melinda Gooderham, Per Soerensen, Philippe ...> ;Journal of the American Academy of Dermatology. 2024 Mar 1
• Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
  Kingston, P., Blauvelt, A., Strober, B., Armstrong, A.> ;Journal of Psoriasis and Psoriatic Arthritis. 2023 Oct 1
• 1 citations
  Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
  Bruce Strober, Laura Ferris, Kristina Callis Duffin, Jud C Janak, Adam P Sima, Thomas Eckmann, Manish Patel, Huzefa Photowala, Vishvas Garg, April Armstrong> ;Journal of the American Academy of Dermatology. 2024 Jan 1
• 11 citations
  Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, pl...
  Akimichi Morita, Bruce Strober, A David Burden, Siew Eng Choon, Milan J Anadkat, Slaheddine Marrakchi, Tsen-Fang Tsai, Kenneth B Gordon, Diamant Thaçi, Min Zheng, Na H...> ;Lancet. 2023 Oct 28
• Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.
  Matthew Bruno, James Q Del Rosso, Bruce Strober> ;The Journal of Clinical and Aesthetic Dermatology. 2023 Sep 1
• 6 citations
  Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIA...
  Bruce Strober, Carle Paul, Andrew Blauvelt, Diamant Thaçi, Luis Puig, Mark Lebwohl, Katy White, Veerle Vanvoorden, Delphine Deherder, Natalie Nunez Gomez, Kilian Eyerich> ;Journal of the American Academy of Dermatology. 2023 Sep 1
• 2 citations
  Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
  Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon, Peter Foley, Phoebe Rich, Carle Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Ku...> ;Immunotherapy. 2023 Aug 1
• Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
  April W Armstrong, Melinda Gooderham, Richard B Warren, Kim A Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C Szepietowski, Shinichi Imafuku, Elizabeth Co...> ;Immunotherapy. 2023 Aug 1
• 1 citations
  JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients.
  Neda Shahriari, Bruce Strober, Mona Shahriari> ;JAAD Case Reports. 2023 Mar 1
• 7 citations
  Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled tri...
  Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B Kimball> ;The British Journal of Dermatology. 2023 Jan 23
• 3 citations
  Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and p...
  Lars E Kristensen, Bruce Strober, Denis Poddubnyy, Ying-Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L Fleishaker, Lara Fallon, Arne Yndestad, Dafna D Gladman> ;Therapeutic Advances in Musculoskeletal Disease. 2023 Jan 1
• 5 citations
  Pharmacology of orismilast, a potent and selective PDE4 inhibitor.
  Jonathan I Silverberg, Lars E French, Richard B Warren, Bruce Strober, Kim Kjøller, Morten O A Sommer, Philippe Andres, Jakob Felding, Anne Weiss, Deniz Tutkunkardas, ...> ;Journal of the European Academy of Dermatology and Venereology. 2023 Apr 1
• 7 citations
  Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.
  Richard B Warren, Bruce Strober, Jonathan I Silverberg, Emma Guttman, Philippe Andres, Jakob Felding, Deniz Tutkunkardas, Kim Kjøller, Morten O A Sommer, Lars E French> ;Journal of the European Academy of Dermatology and Venereology. 2023 Apr 1
• 6 citations
  Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry.
  Alexis Ogdie, Ryan W Harrison, Robert R McLean, Tin-Chi Lin, Mark Lebwohl, Bruce E Strober, Joe Zhuo, Vardhaman Patel, Philip J Mease> ;Journal of the American Academy of Dermatology. 2022 Dec 1
• 5 citations
  Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/I...
  Georgios Kokolakis, Richard B Warren, Bruce Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Di...> ;The British Journal of Dermatology. 2023 Feb 22
• 65 citations
  Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3...
  Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon, Peter Foley, Phoebe Rich, Carle Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Ku...> ;Journal of the American Academy of Dermatology. 2023 Jan 1
• 1 citations
  Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.
  Bruce Strober, Dhaval Patil, Robert R McLean, Melissa Moore-Clingenpeel, Ning Guo, Eugenia Levi, Mark Lebwohl> ;The Journal of Dermatological Treatment. 2022 Dec 1
• 1 citations
  Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
  Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu, Huzefa Photowala, Jeffrey Crowley> ;The Journal of Dermatological Treatment. 2022 Nov 1
• 86 citations
  Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo...
  April W Armstrong, Melinda Gooderham, Richard B Warren, Kim A Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C Szepietowski, Shinichi Imafuku, Elizabeth Co...> ;Journal of the American Academy of Dermatology. 2023 Jan 1
• Join now to see all

Journal Articles

• Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis  
  Tan H, Gupta P, Harness J, Wolk R, Chapel S, Menter A, Strober B, Langley RG, Krishnaswami S, Papp KA, CPT: Pharmacomet Syst Pharmacol, 1/1/2013

Books/Book Chapters

• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Chapter 220: "Topical and Intralesional Cytotoxic Agents" 
  Moore MM and Strober BEEditors: K. Wolff, et al..McGraw-Hill Companies, Inc., USAEdition 7th,2008
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Chapter 214: "Principles of Topical Therapy" 
  Bergstrom KG, Strober BEEditors: K. Wolff, et al..McGraw-Hill Companies, Inc., USAEdition 7th,2008
• Psoriasis and Psoriatic Arthritis: An Integrated Approach 
  Chapter: Chapter XA2: "TNF Antagonist Therapy" 
  Strober BEEditors: K.B. Gordon and E.M. Ruderman.Springer Berlin Heidelberg, New York2005
• Seminars in Cutaneous Medicine and Surgery 
  Chapter: Chapter 24: "The Treatment of Psoriasis with Etanercept" 
  Page 28 - 36Strober BEEditors: J. Sobell.W.B. Saunders Co., Ltd.Edition 1st,2005
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Chapter 242: "Principles of Topical Therapy" 
  Page 2578 - 2584Strober BE, Washenik K, Shupack JLEditors: IM Freedberg, et al..McGraw Hill, USAEdition 6th,2003
• Current Dermatologic Diagnosis and Treatment 
  Chapter: Arthropod Bites 
  Strober BE, Day DJEditors: IM Freedberg and MR Sanchez.Lippincott Williams & Wilkins, Philadelphia2001
• Current Dermatologic Diagnosis and Treatment 
  Chapter: Granulomatous Processes 
  Strober BE, Stern RLEditors: IM Freedberg and MR Sanchez.Lippincott Williams & Wilkins, Philadelphia2001
• Current Dermatologic Diagnosis and Treatment 
  Chapter: Hypertrichosis and Hirsutism 
  Strober BE, Nanni CNEditors: IM Freedberg and MR Sanchez.Lippincott Williams & Wilkins, Philadelphia2001
• Join now to see all

Abstracts/Posters

• Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
  Strober B, Menter A, Leonardi C, Goyal K, Langholff W, Calabro S, Fakharzadeh S, 23rd Congress of the EADV, Amsterdam, The Netherlands, 1/1/2014
• Psoriasis Patients with PASI90 Response Achieve Greater Health-related Quality of Life Improvements than Those with PASI75 Response
  McLeod L, Mallya U, Fox T, Strober B, 23rd Congress of the EADV, Amsterdam, The Netherlands, 1/1/2014
• Phase 2 Study of Brodalumab (AMG827) For Moderate-to-severe Plaque Psoriasis: Week 12 Results on Efficacy and Safety in Patients with Psoriatic Arthritis
  Papp KA, Menter A, Ortonne J-P, Strober B, Kricorian G, Thompson EH, Milmont CE, Nirula A, Klekotka P, CDA 89th Annual Conference, Toronto, Ontario, Canada, 1/1/2014
• Psoriasis Longitudinal Assessment and Registry (PSOLAR): Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Papp K, Augustin M, Ho V, Leonardi C, Menter A, Strober B, Calabro S, Langholff W, Fakharzadeh S, Chevrier M, CDA 89th Annual Conference, Toronto, Ontario, Canada, 1/1/2014
• Improvement of Psoriasis in Subjects with and without Psoriatic Arthritis: Subanalysis of a Brodalumab (AMG 827) Phase 2 Study for Moderate to Severe Plaque Psoriasis
  Papp K, Menter A, Strober B, Kricorian G, Thompson EHZ, Milmont CE, Nirula A, Klekotka P, AAD 72nd Annual Meeting, Denver, Colorado, 1/1/2014
• Psoriasis Longitudinal Assessment and Registry (PSOLAR): Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Strober B, Menter A, Leonardi C, Chevrier M, AAD 72nd Annual Meeting, Denver, Colorado, 1/1/2014
• Secukinumab Impact on Patient-reported Psoriasis Symptoms of Pain, Itching, and Scaling Compared to Placebo and Etanercept (FIXTURE Study).
  Strober B, Gottlieb A, Notter M, Tran MH, AAD 72nd Annual Meeting, Denver, Colorado, 1/1/2014
• Brodalumab (AMG 827) Phase 2 Study for Moderate to Severe Plaque Psoriasis: Subanalysis of Efficacy and Safety in Subjects with Psoriatic Arthritis
  Papp K, Menter A, Ortonne J-P, Strober B, Kricorian G, Thompson E, Milmont C, Nirula A, Klekotka P, 22nd Congress of the EADV, Istanbul, Turkey, 1/1/2013
• PSOLAR: Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Papp K, Augustin M, Strober B, Ho V, Fakharzadeh S, Calabro S, Langholff W, Chevrier M, on behalf of the PSOLAR Steering Committee, 4th Congress of the Psoriasis International Network, Paris, France, 1/1/2013
• Malignancy Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations
  Langley R, Strober B, Lebwohl M, Chevrier M, CDA 88th Annual Conference, Quebec City, Quebec, Canada, 1/1/2013
• Long-term Safety of Ustekinumab: 5 Years of Follow-up from the Psoriasis Clinical Development Program including Patients with Psoriatic Arthritis
  Papp K, Griffiths C, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Shen YK, Ho V, Ghislain PD, Strober B, Reich K, EULAR Annual European Congress of Rheumatology, Madrid, Spain, 1/1/2013
• Safety of Ustekinumab from the Placebo-controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
  McInnes I, Papp K, Puig L, Reich K, Ritchlin C, Strober B, Rahman P, Kavanaugh A, Mendelsohn A, Song M, Chan D, Shen YK, Li S, Gottlieb AB, EULAR Annual European Congress of Rheumatology, Madrid, Spain, 1/1/2013
• Infections in the Ustekinumab Psoriasis Clinical Trial Program: Final Report with up to 5 Years of Follow-up
  Strober B, Lebwohl M, Ghislain PD, Szapary P, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Malignancy Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations
  Langley R, Strober B, Chevrier M, Lebwohl M, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• PSOLAR: Global Update of a Multicenter, Open Registry of Psoriasis Patients
  Papp K, Strober B, Chevrier M, Ho V, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Secukinumab Reduces C-reactive Protein Levels in Patients with Moderate to Severe Plaque Psoriasis: Result of a Regimen-finding Study
  Strober B, Guettner A, Sigurgeirrson B, Papavassilis C, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• The Effects of Adalimumab on C-reactive Protein and Sleep in Moderate to Severe Psoriasis Patients with Suboptimal Response to Etanercept, Methotrexate, or Phototherap...
  Strober B, Goldblum O, Wang Y, Poulin Y, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Impact of Sustained Robust Response on Patient-reported Outcomes for Adalimumab-treated Patients with Moderate to Severe Psoriasis: Subanalysis of REVEAL
  Strober B, Sundaram M, Gu Y, Goldblum O, 21st Congress of the EADV, Prague, Czech Republic, 1/1/2012
• PSOLAR: Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Papp K, Strober B, Ho V, Binder C, Calabro S, Langholff W, Chevrier M, 21st Congress of the EADV, Prague, Czech Republic, 1/1/2012
• Long-term Safety of Ustekinumab in Patients with Moderate to Severe Psoriasis through up to 5 Years of Continuous Follow-up
  Papp K, Griffiths CEM, Gordon K, Lebwohl M, Szapary P, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, 21st Congress of the EADV, Prague, Czech Republic, 1/1/2012
• Malignancy Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations
  Langley R, Strober B, Lebwohl M, Ho V, Fiorentino D, Fakharzadeh S, Calabro S, Langholff W, Chevrier M, 21st Congress of the EADV, Prague, Czech Republic, 1/1/2012
• Content Validity of a Novel Patient-reported Psoriasis Symptom Diary for Patients with Moderate-to-severe Plaque Psoriasis
  Lebwohl M, Nyirady J, Gwaltney CJ, Strober BE, 3rd World Psoriasis & Psoriatic Arthritis Conference 2012, Stockholm, Sweden, 1/1/2012
• PSOLAR: Global Update of a Multicenter, Open Registry of Psoriasis Patients
  Papp K, Strober B, Ho V, Binder C, Calabro S, Langholff W, Chevrier M, 3rd World Psoriasis & Psoriatic Arthritis Conference 2012, Stockholm, Sweden, 1/1/2012
• Malignancy Rates in the Ustekinumab Psoriasis Clinical Trial Program: Update with up to 4 Years of Follow-up and Comparisons to the General United States Population
  Papp K, Gordon K, Yeilding N, Szapary PO, Li S, Krueger G, Strober B, Prinz JC, CDA 87th Annual Conference, Ottawa, Ontario, Canada, 1/1/2012
• PSOLAR: Global Update of a Multicenter, Open Registry of Psoriasis Patients
  Papp K, Strober B, Ho V, Binder C, Calabro S, Langholff W, Chevrier M, CDA 87th Annual Conference, Ottawa, Ontario, Canada, 1/1/2012
• Join now to see all

Lectures

• Hand and Foot Psoriasis, Dermatitis, and Other Inflammatory Dermatoses 
  American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019
• Relationship between Level of Clinical Improvement and Treatment Emergent and Serious Adverse Events: Results from a Placebo-controlled Phase 2 Clinical Trial of Ixeki... 
  Amsterdam, The Netherlands - 1/1/2014
• Biologics Psoriasis Guidelines: Translating Evidence into Practice 
  Chicago, Illinois - 1/1/2014
• Secukinumab's Time to Psoriasis Response on Patient-reported Psoriasis Symptoms (ERASURE Study). 
  Denver, Colorado - 1/1/2014
• Emerging Therapies for Psoriasis 
  Denver, Colorado - 1/1/2014
• Biologic Therapy and Malignancy Risk 
  Denver, Colorado - 1/1/2014
• Management of Hand and Foot Psoriasis 
  Denver, Colorado - 1/1/2014
• The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients 
  Denver, Colorado - 1/1/2014
• Psoriasis Co-morbidities and Prevention of Risk Factors 
  Denver, Colorado - 1/1/2014
• Emerging Biologic Therapies for Psoriasis 
  Naples, Florida - 1/1/2014
• Case-based Discussion on Difficult-to-treat Psoriasis 
  Naples, Florida - 1/1/2014
• Use of Biologics in Hidradenitis Suppurativa 
  Naples, Florida - 1/1/2014
• Psoriasis Longitudinal Assessment and Registry (PSOLAR): Global Update of a Multicentre, Open Registry of Psoriasis Patients 
  Istanbul, Turkey - 1/1/2013
• New Therapies for Psoriasis and Monitoring of Biologics 
  Miami, Florida - 1/1/2013
• Biologics Therapy with Case: Translating Evidence into Practice 
  Boston, Massachusetts - 1/1/2012
• Safety Management of Biologic Agents for Psoriasis 
  Boston, Massachusetts - 1/1/2012
• Comorbidities in Psoriasis: Cardiovascular Risks and Beyond 
  San Diego, California - 1/1/2012
• TNF Inhibitors 
  San Diego, California - 1/1/2012
• Efficacy and Safety of Briakinumab for Treatment of Moderate to Severe Psoriasis in Patients Previously Receiving Etanercept - Results from an Open-label Extension 
  Lisbon, Portugal - 1/1/2011
• Psoriasis Guidelines: Implementing Them in Your Practice 
  New York, New York - 1/1/2011
• The Influence of Body Weight on the Efficacy of Tasocitinib (CP-690,550) In Patients with Plaque Psoriasis 
  Seoul, Korea - 1/1/2011
• The Effect of Tasocitinib (CP-690,550), a Novel Oral Janus Kinase Inhibitor, on Patient-reported Symptoms of Pain and Discomfort Associated with Psoriasis, and Patient... 
  Seoul, Korea - 1/1/2011
• Long-term Safety and Efficacy of Briakinumab for the Treatment of Moderate to Severe Psoriasis - Interim Analysis from an Open-label Extension Study 
  New Orleans, Louisiana - 1/1/2011
• Emerging Therapies in Psoriasis 
  New Orleans, Louisiana - 1/1/2011
• Immunogenicity of Biologic Therapy 
  New Orleans, Louisiana - 1/1/2011
• Join now to see all

Other

• Core Outcome Sets for Psoriasis Clinical Trials 
  Bruce Strober, MD, JAMA
  https://www.doximity.com/articles/8cc1a023-7261-4aa3-a153-dfbe3310e004
  UpToDate, Wolters Kluwer Health - 2013-02-20